These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 26167495)

  • 21. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.
    Ardon H; Van Gool S; Lopes IS; Maes W; Sciot R; Wilms G; Demaerel P; Bijttebier P; Claes L; Goffin J; Van Calenbergh F; De Vleeschouwer S
    J Neurooncol; 2010 Sep; 99(2):261-72. PubMed ID: 20146084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.
    Authier A; Farrand KJ; Broadley KW; Ancelet LR; Hunn MK; Stone S; McConnell MJ; Hermans IF
    Int J Cancer; 2015 Jun; 136(11):2566-78. PubMed ID: 25363661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
    Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
    Front Immunol; 2018; 9():727. PubMed ID: 29910795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune and viral therapies for malignant primary brain tumors.
    Gardeck AM; Sheehan J; Low WC
    Expert Opin Biol Ther; 2017 Apr; 17(4):457-474. PubMed ID: 28274139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular-based immunotherapies for patients with glioblastoma multiforme.
    Xu X; Stockhammer F; Schmitt M
    Clin Dev Immunol; 2012; 2012():764213. PubMed ID: 22474481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Active dendritic cell immunotherapy for glioblastoma: Current status and challenges.
    Polyzoidis S; Tuazon J; Brazil L; Beaney R; Al-Sarraj ST; Doey L; Logan J; Hurwitz V; Jarosz J; Bhangoo R; Gullan R; Mijovic A; Richardson M; Farzaneh F; Ashkan K
    Br J Neurosurg; 2015 Apr; 29(2):197-205. PubMed ID: 25541743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptide vaccines for the treatment of glioblastoma.
    Swartz AM; Batich KA; Fecci PE; Sampson JH
    J Neurooncol; 2015 Jul; 123(3):433-40. PubMed ID: 25491947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cells cross-talk with tumour antigen-specific CD8
    Eiraku Y; Terunuma H; Yagi M; Deng X; Nicol AJ; Nieda M
    Clin Exp Immunol; 2018 Oct; 194(1):54-66. PubMed ID: 30009488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.
    Wang X; Zhao HY; Zhang FC; Sun Y; Xiong ZY; Jiang XB
    Cancer Invest; 2014 Nov; 32(9):451-7. PubMed ID: 25259676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cold Atmospheric Plasma as an Adjunct to Immunotherapy for Glioblastoma Multiforme.
    Almeida ND; Klein AL; Hogan EA; Terhaar SJ; Kedda J; Uppal P; Sack K; Keidar M; Sherman JH
    World Neurosurg; 2019 Oct; 130():369-376. PubMed ID: 31284051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel mechanisms and approaches in immunotherapy for brain tumors.
    Finocchiaro G; Pellegatta S
    Discov Med; 2015; 20(108):7-15. PubMed ID: 26321082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cell immunotherapy for malignant gliomas.
    Luptrawan A; Liu G; Yu JS
    Rev Recent Clin Trials; 2008 Jan; 3(1):10-21. PubMed ID: 18474011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exosomal LGALS9 in the cerebrospinal fluid of glioblastoma patients suppressed dendritic cell antigen presentation and cytotoxic T-cell immunity.
    Wang M; Cai Y; Peng Y; Xu B; Hui W; Jiang Y
    Cell Death Dis; 2020 Oct; 11(10):896. PubMed ID: 33093453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.